WEBULL
News
TGTX
29.19
-0.27%
-0.08
TG Therapeutics announces publication of data from studies on Briumvi
TipRanks · 12h ago
G Therapeutics Publishes Data From Post Hoc Pooled Analysis Of Its Phase 3 ULTIMATE I, II Trials Evaluating BRIUMVI In Participants With Highly Active Relapsing Forms Of Multiple Sclerosis
Benzinga · 13h ago
Weekly Report: what happened at TGTX last week (0302-0306)?
Weekly Report · 14h ago
TG Therapeutics Announces Presentation Dates For BRIUMVI Data On Relapsing Forms Of Multiple Sclerosis
Benzinga · 3d ago
**TG Therapeutics to present BRIUMVI data at AAN 2026 annual meeting**TG Therapeutics Inc. will present two poster sessions on BRIUMVI (ublituximab-xiiy) data in relapsing forms of multiple sclerosis at the American Academy of Neurology 2026 annual meeting in Chicago
Reuters · 3d ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting
Barchart · 3d ago
TG Therapeutics Earnings Call Highlights BRIUMVI Surge
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and TG Therapeutics (TGTX)
TipRanks · 6d ago
Precision to get $7.5M in proceeds from TG Therapeutics for azer-cel milestone
TipRanks · 03/02 12:24
Precision BioSciences Lands $7.5M Milestone Payment From TG Therapeutics In MS Drug Trial
Benzinga · 03/02 12:12
Precision BioSciences Receives $7.5 Million Milestone Payment From TG Therapeutics for Azer-cel MS Trial Progress
Reuters · 03/02 12:01
Weekly Report: what happened at TGTX last week (0223-0227)?
Weekly Report · 03/02 10:20
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth
TipRanks · 03/01 06:00
TG Therapeutics: 'Strong Buy' On BRIUMVI's Massive Growth And Possible Expansion
Seeking Alpha · 02/27 19:31
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
NASDAQ · 02/27 17:08
TG Therapeutics (TGTX) Receives a Sell from Bank of America Securities
TipRanks · 02/27 12:37
Analysts’ Top Healthcare Picks: United Therapeutics (UTHR), TG Therapeutics (TGTX)
TipRanks · 02/26 17:50
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
Seeking Alpha · 02/26 17:28
Buy Rating Backed by Briumvi’s Strong Commercial Ramp, Growing CD20 Market Share, and Visible Long‑Term Revenue Expansion
TipRanks · 02/26 16:45
TG Therapeutics GAAP EPS of $0.14 misses by $0.21, revenue of $192.6M misses by $0.74M
Seeking Alpha · 02/26 12:30
More
Webull provides a variety of real-time TGTX stock news. You can receive the latest news about Tg Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.